Selection of immunochemotherapy for patients with advanced pancreatic cancer
Project/Area Number |
15K09050
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Gastroenterology
|
Research Institution | Jikei University School of Medicine |
Principal Investigator |
Koido Shigeo 東京慈恵会医科大学, 医学部, 准教授 (70266617)
|
Co-Investigator(Kenkyū-buntansha) |
本間 定 東京慈恵会医科大学, 医学部, 教授 (50192323)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | WT1 / 膵癌 / がんワクチン / 免疫療法 / 細胞障害性T細胞 / ペプチドワクチン / 樹状細胞ワクチン / 免疫化学療法 / 免疫誘導 / 樹状細胞 / 集学的免疫化学療法 / 予後バイオマーカー / サイトカイン / 膵臓癌 / 癌局所 / 免疫抑制細胞 |
Outline of Final Research Achievements |
We investigated the efficacy of a Wilms' tumor gene 1 (WT1) peptide vaccine combined with gemcitabine (GEMWT1) and compared it with gemcitabine (GEM) monotherapy for advanced pancreatic ductal adenocarcinoma (PDA) in a randomized phase II study. GEM plus the WT1 peptide vaccine prolonged progression free survival (PFS) and may improve 1-year overall survival (OS)% in patients with PDA. These clinical effects were associated with the induction of WT1-specific immune responses. Moreover, WT1 protein expression was detected in the nucleus and cytoplasm of all PDA cells. OS and disease free survival (DFS) times for patients with PDA following surgical resection demonstrated that the OS and DFS times of patients with weak cytoplasmic WT1 expression were significantly prolonged compared with those of patients with moderate-to-strong cytoplasmic WT1 expression. Therefore, the results support the development of WT1-targeted therapies to prolong survival in all patients with PDA.
|
Report
(4 results)
Research Products
(23 results)
-
[Journal Article] Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study.2018
Author(s)
Nishida S, Ishikawa T, Egawa S, Koido S, Yanagimoto H, Ishii J, Kanno Y, Kokura S, Yasuda H, Oba MS, Sato M, Morimoto S, Fujiki F, Eguchi H, Nagano H, Kumanogoh A, Unno M, Kon M, Shimada H, Ito K, Homma S, Oka Y, Morita S, Sugiyama H.
-
Journal Title
Cancer Immunol Res.
Volume: 6
Issue: 3
Pages: 320-331
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
[Journal Article] Prognostic impact of carbohydrate sulfotransferase 15 in patients with pancreatic ductal adenocarcinoma.2017
Author(s)
Ito Z, Takakura K, Suka M, Kanai T, Saito R, Fujioka S, Kajihara M, Yanagisawa H, Misawa T, Akiba T, Koido S, Ohkusa T.
-
Journal Title
Oncol Lett.
Volume: 13
Issue: 6
Pages: 4799-4805
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
-
[Journal Article] Comprehensive assessment of the prognosis of pancreatic cancer: peripheral blood neutrophil-lymphocyte ratio and immunohistochemical analyses of the tumour site.2016
Author(s)
Takakura K, Ito Z, Suka M, Kanai T, Matsumoto Y, Odahara S, Matsudaira H, Haruki K, Fujiwara Y, Saito R, Gocho T, Nakashiro K, Hamakawa H, Okamoto M, Kajihara M, Misawa T, Ohkusa T, Koido S
-
Journal Title
Scand J Gastroenterol
Volume: 51
Issue: 5
Pages: 610-7
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
-
-
[Journal Article] Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy.2015
Author(s)
Tsukinaga S, Kajihara M, Takakura K, Ito Z, Kanai T, Saito K, Takami S, Kobayashi H, Matsumoto Y, Odahara S, Uchiyama K, Arakawa H, Okamoto M, Sugiyama H, Sumiyama K, Ohkusa T, Koido S
-
Journal Title
World J Gastroenterol
Volume: 21
Issue: 39
Pages: 11168-78
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Randomized, open-label phases II study of WT1 peptide vaccine plus gemcitabine for advanced pancreatic cancer: Clinical efficacy and immune response.2016
Author(s)
Sumiyuki Nishida, Takeshi Ishikawa, Satoshi Kokura, Shin-ichi Egawa, Shigeo Koido, Hiroaki Yasuda, Hiroaki Yanagimoto, Jun Ishii, Yoshihide Kanno, Mari S. Ohba, Maho Sato, Soyoko Morimoto, Hidetoshi Eguchi, Hiroaki Nagano, Sadamu Homma, Yoshihiro Oka, Satoshi Morita, Haruo Sugiyama.
Organizer
ASCO 2016 meeting 第52回 米国癌治療学会議
Place of Presentation
Chicago、USA
Year and Date
2016-06-03
Related Report
Int'l Joint Research
-